Literature DB >> 25613745

Preliminary results of 'liver-first' reverse management for advanced and aggressive synchronous colorectal liver metastases: a propensity-matched analysis.

Kuniya Tanaka1, Takashi Murakami, Kenichi Matsuo, Yukihiko Hiroshima, Itaru Endo, Yasushi Ichikawa, Masataka Taguri, Keiji Koda.   

Abstract

BACKGROUND: Although a 'liver-first' approach recently has been advocated in treating synchronous colorectal metastases, little is known about how results compare with those of the classical approach among patients with similar grades of liver metastases.
METHODS: Propensity-score matching was used to select study subjects. Oncologic outcomes were compared between 10 consecutive patients with unresectable advanced and aggressive synchronous colorectal liver metastases treated with the reverse strategy and 30 comparable classically treated patients.
RESULTS: Numbers of recurrence sites and recurrent tumors irrespective of recurrence sites were greater in the reverse group then the classic group (p = 0.003 and p = 0.015, respectively). Rates of freedom from recurrence in the remaining liver and of freedom from disease also were poorer in the reverse group than in the classical group (p = 0.009 and p = 0.043, respectively). Among patients treated with 2-stage hepatectomy, frequency of microvascular invasion surrounding macroscopic metastases at second resection was higher in the reverse group than in the classical group (p = 0.011).
CONCLUSIONS: Reverse approaches may be feasible in treating synchronous liver metastases, but that strategy should be limited to patients with less liver tumor burden.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25613745     DOI: 10.1159/000370253

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  6 in total

1.  Feasibility of the liver-first approach for patients with initially unresectable and not optimally resectable synchronous colorectal liver metastases.

Authors:  Masayuki Okuno; Etsuro Hatano; Yosuke Kasai; Takahiro Nishio; Satoru Seo; Kojiro Taura; Kentaro Yasuchika; Takashi Nitta; Akira Mori; Hideaki Okajima; Toshimi Kaido; Suguru Hasegawa; Shigemi Matsumoto; Yoshiharu Sakai; Shinji Uemoto
Journal:  Surg Today       Date:  2015-08-28       Impact factor: 2.549

2.  Primary Tumor Versus Liver-First Approach for Synchronous Colorectal Liver Metastases: An Association Française de Chirurgie (AFC) Multicenter-Based Study with Propensity Score Analysis.

Authors:  Francesco Esposito; Chetana Lim; Antonio Sa Cunha; Patrick Pessaux; Francis Navarro; Daniel Azoulay
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

3.  Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.

Authors:  C Lim; A Doussot; M Osseis; F Esposito; C Salloum; J Calderaro; C Tournigand; D Azoulay
Journal:  Clin Transl Oncol       Date:  2018-03-28       Impact factor: 3.405

4.  Liver-first approach of colorectal cancer with synchronous hepatic metastases: A reverse strategy.

Authors:  Jaques Waisberg; Ivan Gregório Ivankovics
Journal:  World J Hepatol       Date:  2015-06-18

5.  A meta-analysis of liver-first versus classical strategy for synchronous colorectal liver metastases.

Authors:  Dimitrios E Magouliotis; George Tzovaras; Alexandros Diamantis; Vasiliki S Tasiopoulou; Dimitris Zacharoulis
Journal:  Int J Colorectal Dis       Date:  2020-01-18       Impact factor: 2.571

6.  Simultaneous, Delayed and Liver-First Hepatic Resections for Synchronous Colorectal Liver Metastases: A Systematic Review and Network Meta-Analysis.

Authors:  Paschalis Gavriilidis; Konstantinos Katsanos; Robert P Sutcliffe; Constantinos Simopoulos; Daniel Azoulay; Keith J Roberts
Journal:  J Clin Med Res       Date:  2019-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.